BELLEVUE, Wash., Feb. 14,
2023 /PRNewswire/ -- Bellevue Life Sciences
Acquisition Corp. (NASDAQ: BLACU, the "Company"), a newly organized
blank check company incorporated in Delaware, today announced that it closed its
initial public offering of 6,000,000 units at a price of
$10.00 per unit. The units are listed
on The Nasdaq Capital Market ("Nasdaq") and began trading under the
ticker symbol "BLACU" on February 10,
2023. Each unit consists of one share of common stock, one
redeemable warrant entitling the holder to purchase one share of
common stock at a price of $11.50 per
share, and one right entitling the holder to receive
one-tenth (1/10th) of one share of common stock upon
consummation of an initial business combination. After the
securities comprising the units begin separate trading, the shares
of common stock, warrants and rights are expected to be listed on
Nasdaq under the symbols "BLAC," "BLACW" and "BLACR,"
respectively.
Chardan acted as sole book-running manager of the offering. The
Company has granted the underwriters a 45-day option to purchase up
to an additional 900,000 units at the initial public offering price
to cover over-allotments, if any.
A registration statement relating to these securities was
declared effective by the U.S. Securities and Exchange Commission
(the "SEC") on February 9, 2023. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
The offering is being made only by means of a prospectus. When
available, copies of the prospectus relating to the offering may be
obtained by contacting Chardan, 17 State Street, Suite 2130
New York, NY 10004. Copies of the
registration statement can be accessed through the SEC's website
at www.sec.gov.
About Bellevue Life Sciences Acquisition Corp.
Bellevue Life Sciences Acquisition Corp. is a blank check
company whose business purpose is to effect a merger, capital stock
exchange, asset acquisition, stock purchase, reorganization or
similar business combination with one or more businesses. While we
will not be limited to a particular industry or geographic region
in our identification and acquisition of a target company, we
intend to focus our search on companies in the healthcare
industry.
Forward Looking Statements
This press release contains statements that constitute
"forward-looking statements," including with respect to the initial
public offering and search for an initial business combination. No
assurance can be given that the proceeds of the offering will be
used as indicated. Forward-looking statements are subject to
numerous conditions, many of which are beyond the control of the
Company, including those set forth in the Risk Factors section of
the Company's registration statement for the initial public
offering filed with the SEC. Copies are available on the SEC's
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
View original
content:https://www.prnewswire.com/news-releases/bellevue-life-sciences-acquisition-corp-announces-closing-of-60-million-initial-public-offering-301746076.html
SOURCE Bellevue Life Sciences Acquisition Corp.
